Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.67 USD | +6.37% | +16.78% | -15.23% |
03-28 | Transcript : Iterum Therapeutics plc, Q4 2023 Earnings Call, Mar 28, 2024 | |
03-28 | Iterum Therapeutics plc Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023 | CI |
Sales 2024 * | - | Sales 2025 * | 12.13M 16.57M | Capitalization | 27.65M 37.76M |
---|---|---|---|---|---|
Net income 2024 * | -38M -51.9M | Net income 2025 * | -19M -25.95M | EV / Sales 2024 * | - |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 2.28 x |
P/E ratio 2024 * |
-0.71
x | P/E ratio 2025 * |
-1.62
x | Employees | 14 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.48% |
Latest transcript on Iterum Therapeutics plc
1 day | +6.37% | ||
1 week | +16.78% | ||
Current month | +8.44% | ||
1 month | +5.03% | ||
3 months | -2.91% | ||
6 months | +149.25% | ||
Current year | -15.23% |
Managers | Title | Age | Since |
---|---|---|---|
Michael Dunne
FOU | Founder | 64 | 15-10-31 |
Corey N. Fishman
FOU | Founder | 59 | 15-06-23 |
Director of Finance/CFO | 54 | 15-10-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Ron Hunt
CHM | Chairman | 59 | 15-10-31 |
Beth Hecht
BRD | Director/Board Member | 60 | 21-03-11 |
Corey N. Fishman
FOU | Founder | 59 | 15-06-23 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-26 | 1.67 | +6.37% | 106,274 |
24-04-25 | 1.57 | +1.29% | 50,986 |
24-04-24 | 1.55 | -1.90% | 36,019 |
24-04-23 | 1.58 | 0.00% | 42,680 |
24-04-22 | 1.58 | +10.49% | 197,643 |
Delayed Quote Nasdaq, April 26, 2024 at 04:30 pm
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-15.23% | 27.65M | |
+1.51% | 42.75B | |
+49.22% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- ITRM Stock